Orion Capital Management LLC Has $30,000 Stock Position in Thermo Fisher Scientific Inc. $TMO

Orion Capital Management LLC decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 51.3% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 75 shares of the medical research company’s stock after selling 79 shares during the period. Orion Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $30,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in TMO. Nuveen LLC acquired a new position in Thermo Fisher Scientific during the 1st quarter worth about $532,360,000. EdgePoint Investment Group Inc. acquired a new position in Thermo Fisher Scientific during the 1st quarter valued at about $172,139,000. Cohen Investment Advisors LLC lifted its position in Thermo Fisher Scientific by 6,655.5% during the 1st quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company’s stock valued at $167,271,000 after purchasing an additional 331,180 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Thermo Fisher Scientific by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock valued at $1,368,859,000 after purchasing an additional 329,974 shares during the period. Finally, Auto Owners Insurance Co lifted its position in Thermo Fisher Scientific by 6,773.5% during the 1st quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company’s stock valued at $143,309,000 after purchasing an additional 283,810 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on TMO. Raymond James Financial restated an “outperform” rating and set a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. William Blair initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an “outperform” rating on the stock. Wells Fargo & Company upped their price target on Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an “overweight” rating in a research note on Thursday. Redburn Partners set a $580.00 price target on Thermo Fisher Scientific in a research note on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday. Nineteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $595.75.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares of the company’s stock, valued at $57,697,567.04. This trade represents a 7.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,666 shares of company stock valued at $13,990,971 over the last ninety days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $573.07 on Friday. The business has a 50 day simple moving average of $504.04 and a 200 day simple moving average of $453.55. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.50 and a current ratio of 1.50. The stock has a market cap of $216.40 billion, a price-to-earnings ratio of 33.11, a PEG ratio of 3.24 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same period in the prior year, the business earned $5.28 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.